Brasília – The National Health Surveillance Agency (Anvisa) has released the list of members of the new Technical Chamber for Clinical Trials on Drugs and Medical Devices (Catepec), which will serve a three-year term. The chamber will provide scientific and technical advice to Anvisa’s directorate, supporting the development of regulatory standards and the monitoring of advances in clinical trials involving drugs, vaccines and medical devices.

The creation of Catepec follows a public call issued in 2024 to select professionals with expertise in evaluating clinical trial protocols and methodologies. Members include representatives from academia, the public sector, research institutions and clinical investigators, who will contribute to discussions on safety, efficacy and innovation in clinical development.

The group’s mandate includes supporting Anvisa in harmonizing national rules with international standards, promoting regulatory convergence and improving transparency in the approval of clinical trials. Catepec will also help define agendas for studies of emerging technologies and propose improvements to simplify processes and accelerate research without compromising patient safety.

Source: Anvisa

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com